Nyxoah Secures $15M from EIB to Accelerate Genio's Launch in the US
Nyxoah announced on Wednesday the release of the second tranche of its financing from the European Investment Bank (EIB), amounting to $15 million. This non-dilutive funding comes just days after closing a $95 million equity fundraising, bringing the total capital raised in June to approximately $110 million.
Non-dilutive Financing to Speed Up Commercial Launch
The EIB funds will be primarily dedicated to accelerating the commercial launch of the Genio system in the United States, while supporting investments in research and development as well as the development of production capacity. Olivier Taelman, CEO, praises the 'continuous support' from the European Investment Bank as 'a strong testament to the confidence in our technology and the long-term potential of our mission'.
Financial Expansion in North America
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
The release of this tranche follows the recent confirmation that Nyxoah had met the predefined criteria to access it. Combined with this month's completed public equity offering, this EIB funding completes an intense period of financial structuring aimed at supporting the group's expansion in North America.
Related
SectorDispositifs médicaux et optique›Dispositifs médicaux
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: T3 2026
Key reported figures
Revenue: 9,2 millions d'euros
Quarterly revenue: 9,2 millions d'euros
Revenue growth: 366,5 %
Guidance from the release
Bien que nous soyons déçus d'ajuster nos prévisions de chiffre d'affaires
Risks mentioned
Ajustement à la baisse des prévisions de chiffre d'affaires (de 36-40 M€ à 33-35 M€)
Trajectoire de croissance inférieure aux attentes pour l'exercice 2026
Dépendance à la ramp-up des États-Unis reflétant les cycles historiques d'une nouvelle technologie
Opportunities identified
Supplément PMA soumis à la FDA pour étendre l'indication américaine aux patients atteints de collapsus concentrique complet
Croissance séquentielle de 29 % du chiffre d'affaires aux États-Unis au T3 2026
Expansion du nombre de chirurgiens formés (342 cumulés) et comptes activés (233 à fort volume) aux États-Unis
Outlook / guidance
Expected revenue: 34 millions d'euros
Management commentary: The Company now expects global net revenue for the full year 2026 to be in the range of €33 million to €35 million, compared to €36 million to €40 million previously.
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
